Analytical Development and Quality Control (ADQC), Byondis B.V., Nijmegen, The Netherlands.
Downstream Processing (DSP), Byondis B.V., Nijmegen, The Netherlands.
Electrophoresis. 2023 Jan;44(1-2):62-71. doi: 10.1002/elps.202200140. Epub 2022 Aug 16.
Antibody-drug conjugates (ADCs) are a prospective class of new oncology therapeutics with the ability to deliver a cytotoxic drug to a targeted location. The concept appears simple, but ADCs are highly complex due to their intrinsic heterogeneity. Randomly conjugated ADCs, for instance, are composed of conjugated species carrying between 0 and 8 linker-drug molecules, with several positional isomers that vary in drug distribution across the antibody. The drug load, expressed as drug-to-antibody ratio (DAR), is a critical quality attribute and should be well controlled, together with the distribution of drug molecules. Here, the impact of the duration of disulfide bond reduction on the DAR was investigated by quantitating the (isomeric) DAR species in ADCs produced with varying reduction times. Although hydrophobic interaction chromatography showed a constant DAR value as a function of reduction time, data obtained by non-reducing CE-SDS revealed an unexpected dynamic in the positional conjugated isomers. The insights obtained have improved our understanding of the correlation between the disulfide bond reduction, an important step in the manufacturing of a cysteine-conjugated ADC, and the conjugational heterogeneity.
抗体偶联药物(ADCs)是一类有前景的新型肿瘤治疗药物,能够将细胞毒性药物递送到靶向位置。这个概念看起来很简单,但由于其内在的异质性,ADC 非常复杂。例如,随机偶联的 ADC 由携带 0 到 8 个连接子-药物分子的偶联物组成,具有几种在抗体上药物分布不同的位置异构体。药物载量(以药物-抗体比(DAR)表示)是一个关键的质量属性,应与药物分子的分布一起得到很好的控制。在这里,通过定量分析具有不同还原时间的 ADC 中(异构的)DAR 物质,研究了二硫键还原持续时间对 DAR 的影响。尽管疏水相互作用色谱法显示出随着还原时间的变化,DAR 值保持不变,但非还原 CE-SDS 获得的数据揭示了位置共轭异构体中出乎意料的动态变化。这些结果提高了我们对二硫键还原(半胱氨酸偶联 ADC 制造中的重要步骤)与偶联异质性之间相关性的理解。